Guangdong Jinmeiji Group is an enterprise that integrates drug production and R&D, drug distribution and sales, as well as medical services and healthcare within its industrial park. With 29 years of history, the company operates four GMP production lines, several GSP-certified companies, and general hospitals. Drawing on extensive experience in pharmaceutical research, production, management, and marketing, along with a robust quality management system, its subsidiary Everon Healthcare specializes in leading and uniquely crafted recombinant humanized type III collagen technology.

This white book adopts a rigorous scientific approach and a broad industry perspective. It starts by exploring foundational research on collagen, offering a thorough explanation of its definition, classification, structural characteristics, and vital role within the human body. It delves particularly into the discovery and structural features of Type III collagen, highlighting its phenomenal contributions to maintaining skin stability, tissue elasticity, and wound healing. At the same time, we highlight the innovative advancements in recombinant Type III triple-helix collagen technology. This includes its design principles, production methods, and bioactivity assessment, demonstrating the significant advantages of this technology in enhancing purity, safety, and adaptability.

Notably, Everon Healthcare has successfully applied recombinant Type III triple-helix collagen, offering a glimpse into the extensive application potential of this technology. Its prospects span multiple fields, including medical specialties, medical aesthetics, and functional skincare industries. With a fully humanized design, AI-assisted optimization, and high-temperature stable triple-helix structure, Everon Healthcare is at the forefront of industry innovation. These advancements provide patients with safer and more effective treatment options, setting a new standard in the field. It provides more possibilities for those pursuing beauty and health, making beauty more efficient and trustworthy. This trusted ingredient marks the beginning of a new era in humanity's pursuit of beauty, offering unlimited benefits and opportunities to explore aesthetics further.

Looking ahead, the future of recombinant Type III triple-helix collagen technology holds immense promise. As research advances and technology evolves, we are confident that this innovation will showcase its unique value across an even wider range of fields. It has the potential to drive breakthroughs in the medical aesthetics industry and contribute significantly to human health. At Everon Healthcare, we believe this triple-helix ingredient marks the starting point of our journey in synthetic biology, and our goal remains to deliver more groundbreaking raw material technologies to benefit people. Together, let us explore the untapped potential of this field and usher in a new era of health and beauty.

As the General Manager of Everon Healthcare, I am truly honored to be part of this meaningful endeavor. As a member of the Jinmeiji Group, I aspire for our contributions in medicine and pharmaceuticals to explore beyond saving lives and alleviating pain, but also to help sustain and strengthen people’s enduring pursuit of beauty. Medical aesthetics, with safe and reliable ingredients, not only treat physical illnesses but also foster confidence and well-being in our society, propelling human progress in beauty and relaxation. I am confident that the release of the "2024 White Book on Recombinant Type III triple-helix Collagen" will become a significant milestone in advancing this field. Let this be the foundation for continued dedication and progress, as we jointly create a healthier and more beautiful in the future.

—— Aries Yang, Chief Executive Officer of Everon Healthcare